Eli Lilly and Company (LLY) Gets Upgraded to Buy From Hold by Freedom Capital
Eli Lilly and Company (NYSE:LLY) is one of the best medical research stocks to buy according to hedge funds.
Eli Lilly & Co (LLY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 4,606,327 | $4,950,328,353 | +4% | 1.69% |
| 2. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,208,336 | $1,298,574,533 | +641% | 1.18% |
| 3. | 322,800 | $346,906,704 | +19% | 0.65% | |
| 4. | Squarepoint Ops LLC Maxime Fortin (Cio) | 209,733 | $225,395,860 | -54% | 0.24% |
| 5. | 208,800 | $224,393,184 | -39% | 0.24% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $691.79 | 715 | $494,626.99 | 14,685 | 2025-08-15 | Filing | |
| $660.25 | 758 | $500,472.53 | 758 | 2025-08-13 | Filing | |
| $647.36 | 1,000 | $647,360.00 | 20,562 | 2025-08-13 | Filing | |
| $644.77 | 1,632 | $1,052,263.01 | 546,601 | 2025-08-12 | Filing | |
| $634.41 | 1,000 | $634,405.00 | 137,660 | 2025-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1,116.69 | 2,737 | $3,056,369.58 | 91,896,978 | 2026-01-07 | Filing | |
| $1,115.76 | 2,210 | $2,465,831.81 | 91,899,715 | 2026-01-07 | Filing | |
| $1,114.37 | 4,342 | $4,838,603.22 | 91,901,925 | 2026-01-07 | Filing | |
| $1,113.77 | 9,053 | $10,082,968.86 | 91,906,267 | 2026-01-07 | Filing | |
| $1,112.43 | 4,652 | $5,175,038.32 | 91,915,320 | 2026-01-07 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 92,190,516 | $99,075,303,735 | 100% | |
| 2. | 81,965,974 | $88,087,192,938 | 1.28% | |
| 3. | 66,792,863 | $71,780,953,971 | 1.21% | |
| 4. | 51,316,011 | $55,148,290,702 | 30.12% | |
| 5. | 24,566,846 | $26,401,595,560 | 4.87% |
News See All
Eli Lilly (LLY) Retains Buy Rating on Strong 2026 Outlook
Eli Lilly & Company (NYSE:LLY) ranks among the best high growth high margin stocks to buy now.
10 Best Medical Research Stocks to Buy According to Hedge Funds
On January 27, Sarah James, Cantor Fitzgerald analyst, appeared on CNBC’s ‘Squawk on the Street’ to talk about the healthcare insurance sector and the stocks coming under pressure.
Eli Lilly and Company (LLY) to Acquire Orna Therapeutics in $2.4B Deal to Expand RNA Pipeline
On February 9, Eli Lilly and Company (NYSE:LLY) announced an agreement to acquire Orna Therapeutics in a transaction valued at up to $2.4 billion in cash.
13 Best Roth IRA Stocks to Buy Now
A Roth IRA, or individual retirement account, is a tax-advantaged way to save for retirement and is not tied to an employer plan like a 401(k).
Robust Demand for Eli Lilly and Company (LLY)’s Obesity and Diabetes Treatments Drives Strong Investor Sentiment
As of February 6, 2026, robust demand for the company’s obesity and diabetes treatments continues to drive strong investor sentiment.
13 Best Performing S&P 500 Stocks in the Last 5 Years
As per Reuters’ year-end report, U.S. equities ended 2025 at record highs.
Eli Lilly (LLY) is "the Great Drug Company on Earth," Says Jim Cramer
Healthcare giant Eli Lilly and Company (NYSE:LLY) is one of Cramer’s top stocks in the sector.
Analysts Project Eli Lilly (LLY) to Deliver 21%+ Revenue Growth and 40%+ Adjusted Earnings Growth in 2026
On February 2, 2026, Reuters reported that long-standing expectations that the global obesity drug market would reach $150 billion over the next decade are being reconsidered amid declining U.S.
Hedge Fund Resource Center Billionaire Hedge Funds
